½ÃÀ庸°í¼­
»óǰÄÚµå
1555526

¼¼°èÀÇ ¼º±â Ç츣Æä½º ½ÃÀå : À¯Çüº°, Åõ¿© °æ·Îº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¹× ¿¹Ãø(2024-2032³â)

Genital Herpes Market, By Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: AnalystView Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® 398 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¼º±â Ç츣Æä½º ½ÃÀå ±Ô¸ð´Â 2023³â 9¾ï 8,767¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³â°£ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 4.89%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼º±â Ç츣Æä½º ½ÃÀå - ½ÃÀå ¿ªÇÐ

¼º±â Ç츣Æä½º À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼º±â Ç츣Æä½º´Â Àü ¼¼°èÀûÀ¸·Î °¡Àå ÈçÇÑ ¼ºº´(STI)À¸·Î ²ÅÈü´Ï´Ù. ÀÌ ÁúȯÀÇ À¯º´·ü Áõ°¡´Â Áø´Ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¿Í È¿°úÀûÀÎ ´ëü Ä¡·áÀÇ Çʿ伺 ¸ðµÎ¿¡ ¿µÇâÀ» ¹ÌÄ¡¸ç ½ÃÀå¿¡ ´Ù¾çÇÑ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é Àü ¼¼°è 50¼¼ ¹Ì¸¸ÀÇ ¾à 37¾ï ¸í(67%)ÀÌ Ç츣Æä½º ¹ÙÀÌ·¯½º 1Çü(HSV-1)¿¡ °¨¿°µÇ¾î ÀÖÀ¸¸ç, ÀÌ ¹ÙÀÌ·¯½º´Â ÁÖ·Î ±¸¼ø Æ÷ÁøÀ» À¯¹ßÇÕ´Ï´Ù. ¶ÇÇÑ ¼º±â Ç츣Æä½ºÀÇ ÁÖ¿ä ¿øÀÎÀÎ Ç츣Æä½º ¹ÙÀÌ·¯½º 2Çü(HSV-2)¿¡ °¨¿°µÈ 15-49¼¼ Àα¸´Â Àü ¼¼°èÀûÀ¸·Î ¾à 4¾ï 9,100¸¸ ¸í(13%)À¸·Î Ãß»êµË´Ï´Ù. ¶ÇÇÑ, Ç츣Æä½º ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ¹é½Å ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ¾î ½ÃÀå ¼ºÀåÀÇ Å« ±âȸ°¡ µÇ°í ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ ³ôÀº Ä¡·áºñ¿ëÀº ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

¼º±â Ç츣Æä½º ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®°¡ °øÀ¯ÇÑ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¿¬Æò±Õ ¾à 4.89%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

Åõ¿© °æ·Î ¼¼ºÐÈ­¿¡ µû¶ó °æ±¸¿ëÀº 2023³â¿¡ °¡Àå ³ôÀº ½ÃÀå Á¡À¯À²À» º¸¿´½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°·Î´Â 2023³â ¼Ò¸Å ¾à±¹ÀÌ ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ÁÖ¿ä ¼öÀÍ¿øÀ¸·Î ºÎ»óÇß½À´Ï´Ù.

¼º±â Ç츣Æä½º ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ¼º±â Ç츣Æä½º ½ÃÀåÀº À¯Çü, Åõ¿© °æ·Î, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº À¯Çü¿¡ µû¶ó Áø´Ü°ú Ä¡·áÀÇ µÎ °¡Áö ºÎ¹®À¸·Î ³ª´¹´Ï´Ù. Áö¼ÓÀûÀÎ ¿¬±¸¿Í ÀÎ½Ä Áõ°¡·Î Áø´Ü ¹× Ä¡·á ½ÃÀåÀº ¸ðµÎ ¼ºÀåÇÏ¿© ȯÀÚ¿Í ÀÇ·á Àü¹®°¡¿¡°Ô °³¼±µÈ ¼Ö·ç¼ÇÀ» Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀº Åõ¿© °æ·Î¿¡ µû¶ó °æ±¸, ÁÖ»çÁ¦, ±¹¼Ò µî ¼¼ °¡Áö ºÎ¹®À¸·Î ºÐ·ùµË´Ï´Ù. °æ±¸¿ë ¾à¹°Àº Àü½Å È¿°ú¿Í »ç¿ë ÆíÀǼºÀ¸·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, ±¹¼Ò Ä¡·á´Â Ç¥ÀûÈ­µÈ ¿ÏÈ­¸¦ Á¦°øÇÕ´Ï´Ù. ÁÖ»çÁ¦´Â ³Î¸® º¸±ÞµÇÁö´Â ¾Ê¾ÒÁö¸¸ ½É°¢ÇÑ Áõ»óÀ» °ü¸®ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ¿Â¶óÀÎ ¾à±¹ ¹× ±âŸ µÎ °¡Áö ÁÖ¿ä ¹üÁÖ·Î ³ª´¹´Ï´Ù. ¼Ò¸Å ¾à±¹Àº ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¼Ò¸Å ¾à±¹Àº 󹿾à°ú ÀÏ¹Ý ÀǾàǰ ¸ðµÎ¿¡ ´ëÇÑ Ä¡·á Á¢±Ù¼ºÀ» Á¦°øÇϰí ȯÀÚ ±³À°À» ÃËÁøÇϸç ÀÇ·á ¼­ºñ½º Á¦°øÀ» °­È­ÇÔÀ¸·Î½á ¼º±â Ç츣Æä½º ºÐ¾ß¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¼º±â Ç츣Æä½º ½ÃÀå - Áö¸®Àû ÅëÂû·Â

¼º±â Ç츣Æä½º ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¸¦ Æ÷ÇÔÇÑ ±¤¹üÀ§ÇÑ Áö¿ª¿¡ °ÉÃÄ ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº »ç¾÷ Ȱµ¿¿¡ ±â¿©ÇÏ´Â ±¹°¡¿¡ µû¶ó ´õ ¼¼ºÐÈ­µË´Ï´Ù. ºÏ¹Ì´Â ÁÖ·Î µ¿¼º¾ÖÀÚµé »çÀÌ¿¡¼­ ¼º±â Ç츣Æä½º Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ¼º±â Ç츣Æä½º À¯º´·üÀÌ ³ôÀ¸¸ç, Àα¸ÀÇ »ó´ç¼ö°¡ HSV-1 ¹× HSV-2¿¡ °¨¿°µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº À¯º´·üÀº öÀúÇÑ Áø´Ü ¹× Ä¡·á ¿É¼ÇÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº ½ÃÀå¿¡¼­ È¿°úÀûÀÌ°í ¾ÈÀüÇÑ ¾à¹°À» »ç¿ëÇÒ ¼ö ÀÖµµ·Ï »õ·Î¿î Ä¡·á¹ýÀ» ½ÂÀÎÇÏ°í ±ÔÁ¦ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³ÀÇÇеµ¼­°ü¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ½Å»ý¾Æ 1,000¸í Áß 1¸íÀÌ ½Å»ý¾Æ Ç츣Æä½º °¨¿°À¸·Î Áø´Ü¹Þ°í ÀÖÀ¸¸ç, »ê¸ð°¡ ÀӽŠÁß »ý½Ä±â HSV °¨¿°À» ¾Î°í žƿ¡°Ô °¨¿°µÉ °æ¿ì ±× À§ÇèÀº ´õ¿í ³ô¾ÆÁý´Ï´Ù. À¯·´Àº ¼º±â Ç츣Æä½ºÀÇ ³ôÀº À¯º´·ü°ú ÀÎÁöµµ·Î ÀÎÇØ ½ÃÀå ¼ºÀå¿¡ ÀÖ¾î µÎ ¹øÂ°·Î Å« Áö¿ªÀ¸·Î ²ÅÈ÷°í ÀÖ½À´Ï´Ù.

¼º±â Ç츣Æä½º ½ÃÀå - °æÀï ±¸µµ :

¼º±â Ç츣Æä½º ½ÃÀåÀº Áø´Ü Å×½ºÆ® ¹× Ä¡·á ¿É¼ÇÀÇ °³¹ß, »ý»ê ¹× À¯Åë¿¡ Á¾»çÇÏ´Â ¼ö¸¹Àº ÁøÀÔÀÚ°¡ ÀÖ´Â °æÀïÀûÀΠȯ°æÀ¸·Î Ư¡ÁöÀ» ¼ö ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº º¸´Ù Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´Ü Å×½ºÆ® °³¹ßÀ» À§ÇÑ ÅõÀÚ¸¦ ¿ì¼±¼øÀ§·Î »ï°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦Ç° Á¢±Ù¼ºÀ» ³ôÀ̱â À§ÇØ »õ·Î¿î ½ÃÀå°ú Áö¿ªÀ¸·ÎÀÇ ÁøÃâÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»ç, Áø´Ü Å×½ºÆ® Á¦Á¶¾÷ü, ¼Ò¸Å ¾à±¹µéÀº °¢°¢ ¼º±â Ç츣Æä½º Ä¡·á¿Í Áø´ÜÀ» Á¦°øÇÏ´Â µ¥ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼º±â Ç츣Æä½º ½ÃÀå °³¿ä

  • Á¶»ç ¹üÀ§
  • ½ÃÀå ÃßÁ¤ ¿¬µµ

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ºÐ¼®
  • °æÀï ÀλçÀÌÆ®

Á¦3Àå ¼º±â Ç츣Æä½º ÁÖ¿ä ½ÃÀå µ¿Çâ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ½ÃÀå ÇâÈÄ µ¿Çâ

Á¦4Àå ¼º±â Ç츣Æä½º ¾÷°è Á¶»ç

  • PEST ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • ¼ºÀå Àü¸Á ¸ÅÇÎ
  • ±ÔÁ¦ ±¸Á¶ ºÐ¼®

Á¦5Àå ¼º±â Ç츣Æä½º ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

  • COVID-19 ÀÌÀüÀÇ ¿µÇ⠺м®
  • COVID-19 ÀÌÈÄÀÇ ¿µÇ⠺м®

Á¦6Àå ¼º±â Ç츣Æä½º ½ÃÀå ±¸µµ

  • ¼º±â Ç츣Æä½º ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • ºÐ¼® µ¥ÀÌÅÍ : ÁÖ¿ä Á¦Á¶¾÷üº°
    • ±âÁ¸ ±â¾÷ ºÐ¼®
    • ½Å±Ô ±â¾÷ ºÐ¼®

Á¦7Àå ¼º±â Ç츣Æä½º ½ÃÀå : À¯Çüº°

  • °³¿ä
    • ºÎ¹® Á¡À¯À² ºÐ¼® : À¯Çüº°
    • Áø´Ü
    • Ä¡·á
      • Acyclovir
      • Famciclovir
      • Valacyclovir
      • ±âŸ

Á¦8Àå ¼º±â Ç츣Æä½º ½ÃÀå : Åõ¿© °æ·Îº°

  • °³¿ä
    • ºÎ¹® Á¡À¯À² ºÐ¼® : Åõ¿© °æ·Îº°
    • °æ±¸
    • ÁÖ»çÁ¦
    • ±¹¼Ò

Á¦9Àå ¼º±â Ç츣Æä½º ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
    • ºÎ¹® Á¡À¯À² ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
    • º´¿ø ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • ¿Â¶óÀÎ ¾à±¹
    • ±âŸ

Á¦10Àå ¼º±â Ç츣Æä½º ½ÃÀå : Áö¿ªº°

  • ¼­·Ð
  • ºÏ¹Ì
    • °³¿ä
    • ºÏ¹Ì ÁÖ¿ä Á¦Á¶¾÷ü
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • °³¿ä
    • À¯·´ ÁÖ¿ä Á¦Á¶¾÷ü
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ·¯½Ã¾Æ
    • ³×´ú¶õµå
    • ½º¿þµ§
    • Æú¶õµå
    • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç(APAC)
    • °³¿ä
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ÁÖ¿ä Á¦Á¶¾÷ü
    • Àεµ
    • Áß±¹
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ű¹
    • Àεµ³×½Ã¾Æ
    • Çʸ®ÇÉ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • °³¿ä
    • ¶óƾ¾Æ¸Þ¸®Ä« ÁÖ¿ä Á¦Á¶¾÷ü
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • °³¿ä
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÁÖ¿ä Á¦Á¶¾÷ü
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ÅÍŰ
    • ¾ËÁ¦¸®
    • ÀÌÁýÆ®
    • ±âŸ

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¼º±â Ç츣Æä½º ¾÷°è

  • °æÀï ´ë½Ãº¸µå
  • ±â¾÷ °³¿ä
    • Teva Pharmaceutical Industries Ltd.
    • Abbott Laboratories
    • Sun Pharmaceuticals Industries Ltd.
    • Mylan N.V.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Dr. Reddy's Laboratories, ltd.
    • Novartis AG
    • Valeant Pharmaceuticals International Inc. etc.
    • ±âŸ

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LSH 24.10.18

REPORT HIGHLIGHT

Genital Herpes Market size was valued at USD 987.67 Million in 2023, expanding at a CAGR of 4.89% from 2024 to 2032.

Genital herpes is a prevalent sexually transmitted infection (STI) resulting from the herpes simplex virus (HSV). This condition is marked by recurring episodes of painful sores and blisters in the genital and anal regions. The two types of herpes simplex virus responsible for genital herpes are HSV-1 and HSV-2. According to the World Health Organization, approximately 3.7 billion individuals under the age of 50 were infected with HSV-1 in 2016. Additionally, around 491 million people aged 15 to 49 were reported to have an HSV-2 infection in the same year.

Genital Herpes Market- Market Dynamics

The increasing prevalence of genital herpes is projected to drive the growth of the market

Genital herpes ranks among the most prevalent sexually transmitted infections (STIs) across the globe. The increasing incidence of this condition carries various implications for the market, affecting both the demand for diagnostic services and the necessity for effective treatment alternatives. According to the World Health Organization, approximately 3.7 billion individuals under the age of 50 (67%) worldwide are infected with herpes simplex virus type 1 (HSV-1), which primarily causes oral herpes. Additionally, an estimated 491 million people aged 15 to 49 (13%) globally are affected by herpes simplex virus type 2 (HSV-2), the primary cause of genital herpes. Moreover, ongoing investigations into vaccines for the herpes simplex virus offer a considerable opportunity for market growth. Nevertheless, the high cost of treatment may pose a challenge to the expansion of the market.

Genital Herpes Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.89% over the forecast period (2024-2032)

Based on the Route of administration segmentation, Oral was predicted to show maximum market share in the year 2023

Based on End-User segmentation, Retail Pharmacies were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Genital Herpes Market- Segmentation Analysis:

The Global Genital Herpes Market is segmented based on Type, Route of Administration, End-User, and Region.

The market is classified into two segments according to Type: Diagnosis and Treatment. With ongoing research and heightened awareness, the market for both diagnosis and treatment is anticipated to grow, providing improved solutions for patients and healthcare professionals.

The market is classified into three segments according to the Route of Administration: Oral, Injectable, and Topical. Oral medications lead the market owing to their systemic effectiveness and convenience of use, whereas topical treatments offer targeted relief. Injectable medications, although less prevalent, play a crucial role in managing severe conditions.

The market is segmented into two primary categories according to End-User: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Retail Pharmacies hold a dominant position within the market. They play an essential role in the genital herpes sector by providing access to both prescription and over-the-counter treatments, facilitating patient education, and enhancing healthcare delivery.

Genital Herpes Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads in market growth, primarily driven by the rising demand for genital herpes treatments among homosexual individuals. The region exhibits a significant prevalence of genital herpes, with a considerable segment of the population affected by HSV-1 and HSV-2. This elevated prevalence underscores the need for thorough diagnostic and treatment options. The U.S. Food and Drug Administration (FDA) is instrumental in the approval and regulation of new therapies, ensuring the availability of effective and safe medications in the marketplace. According to the National Library of Medicine, 1 in 1,000 newborns in the United States is diagnosed with neonatal herpes infection, with the risk increasing if the mother contracts genital HSV infection during pregnancy and transmits it to the fetus. Europe ranks as the second-largest region for market growth, attributed to the high prevalence and awareness of genital herpes.

Genital Herpes Market- Competitive Landscape:

The genital herpes market exhibits a competitive environment, characterized by numerous participants engaged in the development, production, and distribution of diagnostic tests and therapeutic options. Manufacturers are prioritizing investments aimed at creating more precise and rapid diagnostic tests. Additionally, they are broadening their reach into new markets and regions to enhance product accessibility. Pharmaceutical firms, diagnostic test manufacturers, and retail pharmacies each contribute significantly to the provision of treatments and diagnostics for genital herpes.

Recent Developments:

In November 2023, Abbott Laboratories obtained approval from the U.S. Food and Drug Administration for its molecular human papillomavirus (HPV) screening test, thereby enhancing the company's portfolio of cancer screening instruments. This latest addition to the Alinity M series of diagnostic assays is suitable for screening by existing guidelines, as well as for diagnostic purposes, and offers comprehensive insights into the genotypes of the virus that may lead to cancer.

In March 2024, Sun Pharmaceutical Industries Inc. announced the recall of 47,520 bottles of the 40 mg medication and 7,488 bottles of the 80 mg formulation, citing deviations from Current Good Manufacturing Practice (CGMP) regulations.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENITAL HERPES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Teva Pharmaceutical Industries Ltd.
  • Abbott Laboratories
  • Sun Pharmaceuticals Industries Ltd.
  • Mylan N.V.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories, ltd.
  • Novartis AG
  • Valeant Pharmaceuticals International Inc. etc.
  • Others

GLOBAL GENITAL HERPES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Diagnosis
  • Treatment
  • Acyclovir
  • Famciclovir
  • Valacyclovir
  • Others

GLOBAL GENITAL HERPES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Topical

GLOBAL GENITAL HERPES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

GLOBAL GENITAL HERPES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Genital Herpes Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Genital Herpes Market Snippet by Type
    • 2.1.2. Genital Herpes Market Snippet by Route of Administration
    • 2.1.3. Genital Herpes Market Snippet by End-User
    • 2.1.4. Genital Herpes Market Snippet by Country
    • 2.1.5. Genital Herpes Market Snippet by Region
  • 2.2. Competitive Insights

3. Genital Herpes Key Market Trends

  • 3.1. Genital Herpes Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Genital Herpes Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Genital Herpes Market Opportunities
  • 3.4. Genital Herpes Market Future Trends

4. Genital Herpes Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Genital Herpes Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Genital Herpes Market Landscape

  • 6.1. Genital Herpes Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Genital Herpes Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Diagnosis
    • 7.1.3. Treatment
      • 7.1.3.1. Acyclovir
      • 7.1.3.2. Famciclovir
      • 7.1.3.3. Valacyclovir
      • 7.1.3.4. Others

8. Genital Herpes Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectable
    • 8.1.4. Topical

9. Genital Herpes Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies
    • 9.1.5. Others

10. Genital Herpes Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Genital Herpes Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Genital Herpes Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Genital Herpes Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Genital Herpes Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Genital Herpes Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Genital Herpes Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Teva Pharmaceutical Industries Ltd.
    • 11.2.2. Abbott Laboratories
    • 11.2.3. Sun Pharmaceuticals Industries Ltd.
    • 11.2.4. Mylan N.V.
    • 11.2.5. Pfizer Inc.
    • 11.2.6. GlaxoSmithKline plc
    • 11.2.7. Dr. Reddy's Laboratories, ltd.
    • 11.2.8. Novartis AG
    • 11.2.9. Valeant Pharmaceuticals International Inc. etc.
    • 11.2.10. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦